Skip to main content
logo
Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
41.82
-0.78 (-1.83%)
At close: Aug 13, 2026, 4:00 PM EDT
42.30
+0.48 (1.15%)
Pre-market: Aug 14, 2026, 8:49 AM EDT

Immunovant Ratios and Metrics

Millions USD. Fiscal year is Apr - Mar.

Total Valuation

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Market Cap
8,6385,0662,9074,7042,021642
Market Cap Growth
225.80%74.25%-38.19%132.70%214.95%-59.16%
Enterprise Value
7,8404,1642,1934,0691,646150.37
Last Close Price
41.8224.8417.0932.3115.515.51

Price Ratios

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
PB Ratio
11.735.944.117.615.581.37
P/TBV Ratio
10.875.323.667.225.271.29

Financial Efficiency

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Debt / Equity Ratio
-0000.000.00
Net Debt / Equity Ratio
-1.08-1.06-1.01-1.03-1.03-1.05
Net Debt / EBITDA Ratio
1.411.691.632.251.723.15
Net Debt / FCF Ratio
1.932.221.902.961.994.62
Quick Ratio
6.828.6510.4113.188.7111.37
Current Ratio
7.279.0911.1613.709.3411.52
Return on Equity (ROE)
-62.53%-64.82%-62.46%-52.91%-50.69%-36.39%
Return on Assets (ROA)
-59.35%-61.52%-60.88%-52.85%-47.38%-33.61%
Return on Capital Employed (ROCE)
-65.76%-68.32%-66.13%-57.68%-52.37%-36.09%

Yields

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Buyback Yield / Dilution
-21.12%-20.35%-9.76%-12.21%-12.21%-24.98%
Total Shareholder Return
-21.12%-20.35%-9.76%-12.21%-12.21%-24.98%
SEC Filings: 10-K · 10-Q